MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System
